Dublin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The "Continuous Glucose Monitoring (CGM) Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The Continuous ...

As people around the world seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

In recent years, diabetes management has undergone a remarkable transformation with the rise in continuous glucose monitors (CGMs). These devices present patients with an easier way to maintain ...

The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...

Please provide your email address to receive an email when new articles are posted on . McKee and colleagues conducted a retrospective survey of adults attending the Washington ...

A continuous glucose monitor is a better option than pricking your finger daily. These wearable devices are stuck to your arm and connect to an app on your smartphone or Apple Watch to easily test ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

Walmart will become the first U.S. retailer to sell Abbott’s continuous glucose monitoring device as the medtech giant looks to broaden its sales potential for its growing business unit. | Walmart ...

DexCom is a major player in the continuous glucose monitoring space, with steadily growing revenues and a breakout year in 2020. DXCM's market cap valuation has reached $40 billion, leading to high ...

“Let’s see what a Snickers bar does to my blood sugar,” Justin Richard, a 52-year-old Toronto-based TikToker says just before eating the candy bar on camera. After an edited time skip, Richard says, ...

In a multivariable logistic regression analysis, use of CGM devices was associated with lower odds of diabetic retinopathy (OR 0.52, 95% CI 0.32-0.84, P=0.008) and proliferative diabetic retinopathy ...